Developer docs
API playgroundTry for free, no card

Search company profiles

Primex Pharmaceuticals

Full company profile

uuid000hvz7

Namestring
Primex Pharmaceuticals
Legal namestring
Primex Pharmaceuticals consisting of Primex Pharmaceuticals Oy and its affiliates Primex Pharmaceuticals AG and Giovanni Ogna e Figli S.r.l
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Primex Pharmaceuticals is a privately-held, commercial-stage specialty pharmaceutical company focused on anesthesia and perioperative therapy, operating through three legal entities (Primex Pharmaceuticals Oy in Finland, Primex Pharmaceuticals AG in Switzerland as international headquarters, and Giovanni Ogna e Figli S.r.l in Italy). The company's product portfolio centers on two core platforms: Recofol, a propofol-based intravenous anesthetic acquired from Bayer in 2011 with MCT/LCT, EDTA-preserved, and veterinary formulations for anesthesia and ICU sedation; and OZALIN/OZASED, a 2mg/ml oral midazolam solution developed at Amiens Hospital in France and approved across 16 European countries as the only product indicated for pediatric procedural sedation (infants from 6 months through adolescents). The 2024 acquisition of Ogna added a nearly 90-year Italian dental pharmaceutical brand featuring local anesthetics (articaine, mepivicaine, lidocaine) and CE-marked endodontic medical devices. Manufacturing is fully outsourced, with EU-based production, while the company retains global regulatory, distribution, and marketing functions.

Primex operates an asset-light, partner-mediated go-to-market model in which regional partners serve as local Marketing Authorization Holders, sales, marketing, and distribution entities across 40+ countries spanning Europe, Mexico, Latin America, Southeast Asia (Indonesia), and MENA. The company generates revenue through branded generic product sales supplemented by licensing and regional divestiture transactions—most notably the 2024 European pediatric sedation rights divestiture designed to fund US and China expansion. Customer segments are diversified across hospitals/ICUs/surgical centers, pediatric healthcare providers, and dental practitioners, though all end-customer relationships are intermediated through the Primex Network of regional partners. The company turned profitable in 2012, has been funded by Finnish investors Bocap and Finnvera since 2014, and is currently led by CEO Tomaso Dameno (since end of 2023) with a leadership transition in 2024 bringing CFO Michael Augsberger and in 2025 appointing Bareket Gelbhart as Head of Business Development to lead an active partnering and investor outreach effort.

Short descriptiontext

Primex Pharmaceuticals is a specialty pharmaceutical company developing and commercializing branded anesthesia (Recofol propofol), pediatric procedural sedation (OZALIN/OZASED oral midazolam), and dental products (OGNA), distributed through a regional partner network across 40+ countries for hospitals, pediatric care providers, and dental practitioners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anesthetic pharmaceuticals, pediatric sedation, perioperative therapy, branded generics, dental anesthetics
Industry3 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals (Anesthesia and Pediatric Sedation)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales
TypeOne Time License
Description

Sale of branded generic pharmaceutical products including Recofol (propofol-based anesthesia), OZALIN/OZASED (pediatric sedation), and OGNA dental products (local anesthetics, endodontic devices). Products sold through regional partner network across 40+ countries.

primexpharma.com
2Licensing and Divestiture
TypeLicensing Royalties
Description

European divestiture of pediatric sedation formulation rights completed in 2024, demonstrating strategy of developing and launching products then licensing or divesting regional rights to maximize value creation.

primexpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Recofol
Description

Propofol-based products for anesthesia and ICU sedation, including Recofol N (MCT/LCT formulation), Recofol EDTA (propofol plus EDTA), and Propofo VET (for animals)

primexpharma.com
+2 more records
Core offering1 text field

Primex Pharmaceuticals is a commercial-stage specialty pharmaceutical company that develops, registers and distributes branded generic anesthetic and pediatric sedation products, primarily Recofol (propofol-based IV anesthetics) and OZALIN/OZASED (oral midazolam solution for pediatric procedural sedation), alongside the Ogna dental anesthetic and endodontic portfolio. The company outsources manufacturing and leverages a regional partner network (the "Primex Network") across 40+ countries to serve as local MAH, sales, marketing and distribution partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Primex Pharmaceuticals operates as an international commercial-stage specialty pharmaceutical company focused on anesthesia and perioperative therapy. The company offers a portfolio of branded generic anesthetic pharmaceuticals and innovative pediatric solutions through three integrated entities: Primex Pharmaceuticals Oy (Finland), Primex Pharmaceuticals AG (Switzerland), and Giovanni Ogna e Figli S.r.l (Italy). The product portfolio centers on two core platforms: Recofol (propofol-based IV anesthetic for anesthesia and ICU sedation available as standard MCT/LCT formulation, EDTA variant, and veterinary formulation) and OZALIN/OZASED (2mg/ml oral midazolam solution for pediatric procedural sedation). The Ogna acquisition added a nearly century-old dental portfolio featuring local anesthetics (articaine, mepivicaine, lidocaine) and CE-marked endodontic medical devices. The company outsources manufacturing and focuses on global regulatory affairs, distribution, and marketing through regional partnership networks spanning 40+ countries.

Product and service5 records
1Recofol N
CategoryAnesthesia pharmaceuticals
Description

Propofol intravenous anesthetic with MCT/LCT formulation acquired from Bayer in 2011, used by intensive care units, surgeries and clinics for anesthesia induction, maintenance of anesthesia and ICU sedation.

2Recofol EDTA
CategoryAnesthesia pharmaceuticals
Description

Propofol formulation with EDTA as antimicrobial retardant preservative, compliant with FDA and other regulatory authority requirements. Manufactured in EU.

3OZALIN / OZASED
CategoryPediatric sedation pharmaceuticals
Description

2mg/ml oral midazolam solution (formerly ADV6209) for pediatric procedural sedation. EU-approved for infants from 6 months, children and adolescents for moderate sedation before therapeutic or diagnostic procedures to relieve anxiety, distress and agitation. Developed at Amiens Hospital in France.

4Ogna Local Anaesthetic Portfolio
CategoryDental pharmaceuticals
Description

Local anesthetic products including articaine, mepivicaine and lidocaine in spray and gel forms, from the nearly 90-year-old Italian dental pharmaceutical company Giovanni Ogna e Figli S.r.l.

5Ogna Endodontic Medical Devices
CategoryDental medical devices
Description

CE-marked endodontic medical devices from the Ogna dental portfolio, used by dentists and dental surgeons for endodontic treatments.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Fifteen-year partnership with a 30,000-person Mexican organization. Despite size differential, this relationship has proven exceptional due to product uniqueness and strong personal relationships. One of the company's most successful partnerships.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Italian company specializing in dental products acquired by Primex. Nearly 90-year-old brand with exceptional market recognition in endodontics. Operates domestically in Italy while expanding internationally under its own brand. Products include local anesthetic portfolio (articaine, mepivicaine, lidocaine) and endodontic medical devices (CE marked).

Strategic tierMinorTypeGTM or Marketing Partner
Description

Non-profit initiative of leading paediatric anaesthesiologists that promotes safe conduct of anaesthesia in children. Supported by unrestricted educational grant from Primex Pharmaceuticals.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Standardized quality improvement tool from the International Committee for the Advancement of Procedural Sedation. Primex provides unrestricted educational grant support.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in injectable anesthetics including a major propofol franchise. Direct competitor to Primex in propofol-based anesthesia and ICU sedation across hospital channels.

TypeDirect peer
Description

Specialty generic injectable manufacturer with hospital-channel focus in anesthesia and sedation. Highly comparable business model of branded generics distributed through hospital and institutional customers across multiple regions.

TypeDirect peer
Description

Specialty pharma group that acquires and revitalizes branded generic portfolios globally, often in anesthesia and specialty hospital products. Closely mirrors Primex's acquire-revitalize-distribute playbook.

TypeEmerging player
Description

Swiss specialty injectable pharmaceutical company with focus on anesthesia, analgesia, and CNS products. Direct overlap in hospital-channel injectable anesthetics and similar mid-sized European specialty profile.

TypeBroad incumbent
Description

European specialty pharma with portfolio of branded specialty products distributed through partners across multiple regions. Similar partner-led European commercial model and acquisition-driven growth.

TypeBroad incumbent
Description

Large European generics and specialty pharma with broad hospital and consumer portfolio. Comparable in its mix of branded generics, specialty focus, and multi-country European presence.

TypeEmerging player
Description

European specialty pharma developing and commercializing injectable anesthetic and sedation agents. Closely aligned with Primex's perioperative and procedural sedation therapeutic focus.

TypeEmerging player
Description

French specialty pharma focused on branded generics and specialty hospital products with European and international reach. Comparable French-anchored specialty pharma profile and partner distribution approach.

TypeEmerging player
Description

European specialty pharma dedicated to pediatric medicines. Directly comparable to Primex's pediatric sedation positioning and addresses similar unmet needs in pediatric formulations.

TypeBroad incumbent
Description

European specialty pharma focused on dermatology and specialty hospital products with partner-led international expansion. Similar mid-sized European specialty pharma profile with bolt-on acquisition strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Primex Pharmaceuticals

Specialty Pharmaceuticals (Anesthesia and Pediatric Sedation)primexpharma.com

Primex Pharmaceuticals is a specialty pharmaceutical company developing and commercializing branded anesthesia (Recofol propofol), pediatric procedural sedation (OZALIN/OZASED oral midazolam), and dental products (OGNA), distributed through a regional partner network across 40+ countries for hospitals, pediatric care providers, and dental practitioners.

What Primex Pharmaceuticals does

Primex Pharmaceuticals is a privately-held, commercial-stage specialty pharmaceutical company focused on anesthesia and perioperative therapy, operating through three legal entities (Primex Pharmaceuticals Oy in Finland, Primex Pharmaceuticals AG in Switzerland as international headquarters, and Giovanni Ogna e Figli S.r.l in Italy). The company's product portfolio centers on two core platforms: Recofol, a propofol-based intravenous anesthetic acquired from Bayer in 2011 with MCT/LCT, EDTA-preserved, and veterinary formulations for anesthesia and ICU sedation; and OZALIN/OZASED, a 2mg/ml oral midazolam solution developed at Amiens Hospital in France and approved across 16 European countries as the only product indicated for pediatric procedural sedation (infants from 6 months through adolescents). The 2024 acquisition of Ogna added a nearly 90-year Italian dental pharmaceutical brand featuring local anesthetics (articaine, mepivicaine, lidocaine) and CE-marked endodontic medical devices. Manufacturing is fully outsourced, with EU-based production, while the company retains global regulatory, distribution, and marketing functions.

Primex operates an asset-light, partner-mediated go-to-market model in which regional partners serve as local Marketing Authorization Holders, sales, marketing, and distribution entities across 40+ countries spanning Europe, Mexico, Latin America, Southeast Asia (Indonesia), and MENA. The company generates revenue through branded generic product sales supplemented by licensing and regional divestiture transactions—most notably the 2024 European pediatric sedation rights divestiture designed to fund US and China expansion. Customer segments are diversified across hospitals/ICUs/surgical centers, pediatric healthcare providers, and dental practitioners, though all end-customer relationships are intermediated through the Primex Network of regional partners. The company turned profitable in 2012, has been funded by Finnish investors Bocap and Finnvera since 2014, and is currently led by CEO Tomaso Dameno (since end of 2023) with a leadership transition in 2024 bringing CFO Michael Augsberger and in 2025 appointing Bareket Gelbhart as Head of Business Development to lead an active partnering and investor outreach effort.

Primex Pharmaceuticals firmographics

Firmographics
Name
Primex Pharmaceuticals
Legal name
Primex Pharmaceuticals consisting of Primex Pharmaceuticals Oy and its affiliates Primex Pharmaceuticals AG and Giovanni Ogna e Figli S.r.l
Website
https://primexpharma.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Primex Pharmaceuticals is a specialty pharmaceutical company developing and commercializing branded anesthesia (Recofol propofol), pediatric procedural sedation (OZALIN/OZASED oral midazolam), and dental products (OGNA), distributed through a regional partner network across 40+ countries for hospitals, pediatric care providers, and dental practitioners.
Ownership category
akta.pro rank

Primex Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals (Anesthesia and Pediatric Sedation)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Anesthetic pharmaceuticals
  • Pediatric sedation
  • Perioperative therapy
  • Branded generics
  • Dental anesthetics

Where Primex Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Primex Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Product Sales: Sale of branded generic pharmaceutical products including Recofol (propofol-based anesthesia), OZALIN/OZASED (pediatric sedation), and OGNA dental products (local anesthetics, endodontic devices). Products sold through regional partner network across 40+ countries.
  2. Licensing and Divestiture: European divestiture of pediatric sedation formulation rights completed in 2024, demonstrating strategy of developing and launching products then licensing or divesting regional rights to maximize value creation.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Primex Pharmaceuticals product offering

Product offering

Core offering

Primex Pharmaceuticals is a commercial-stage specialty pharmaceutical company that develops, registers and distributes branded generic anesthetic and pediatric sedation products, primarily Recofol (propofol-based IV anesthetics) and OZALIN/OZASED (oral midazolam solution for pediatric procedural sedation), alongside the Ogna dental anesthetic and endodontic portfolio. The company outsources manufacturing and leverages a regional partner network (the "Primex Network") across 40+ countries to serve as local MAH, sales, marketing and distribution partners.

Product overview

Primex Pharmaceuticals operates as an international commercial-stage specialty pharmaceutical company focused on anesthesia and perioperative therapy. The company offers a portfolio of branded generic anesthetic pharmaceuticals and innovative pediatric solutions through three integrated entities: Primex Pharmaceuticals Oy (Finland), Primex Pharmaceuticals AG (Switzerland), and Giovanni Ogna e Figli S.r.l (Italy). The product portfolio centers on two core platforms: Recofol (propofol-based IV anesthetic for anesthesia and ICU sedation available as standard MCT/LCT formulation, EDTA variant, and veterinary formulation) and OZALIN/OZASED (2mg/ml oral midazolam solution for pediatric procedural sedation). The Ogna acquisition added a nearly century-old dental portfolio featuring local anesthetics (articaine, mepivicaine, lidocaine) and CE-marked endodontic medical devices. The company outsources manufacturing and focuses on global regulatory affairs, distribution, and marketing through regional partnership networks spanning 40+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Recofol: Propofol-based products for anesthesia and ICU sedation, including Recofol N (MCT/LCT formulation), Recofol EDTA (propofol plus EDTA), and Propofo VET (for animals)
  • OZALIN / OZASED
  • OGNA Dental Portfolio

Products and services

  • Recofol N Propofol intravenous anesthetic with MCT/LCT formulation acquired from Bayer in 2011, used by intensive care units, surgeries and clinics for anesthesia induction, maintenance of anesthesia and ICU sedation.
  • Recofol EDTA Propofol formulation with EDTA as antimicrobial retardant preservative, compliant with FDA and other regulatory authority requirements. Manufactured in EU.
  • OZALIN / OZASED 2mg/ml oral midazolam solution (formerly ADV6209) for pediatric procedural sedation. EU-approved for infants from 6 months, children and adolescents for moderate sedation before therapeutic or diagnostic procedures to relieve anxiety, distress and agitation. Developed at Amiens Hospital in France.
  • Ogna Local Anaesthetic Portfolio Local anesthetic products including articaine, mepivicaine and lidocaine in spray and gel forms, from the nearly 90-year-old Italian dental pharmaceutical company Giovanni Ogna e Figli S.r.l.
  • Ogna Endodontic Medical Devices CE-marked endodontic medical devices from the Ogna dental portfolio, used by dentists and dental surgeons for endodontic treatments.

Companies that use Primex Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles4 records

Primex Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Primex Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Mexican PartnercoreChannel Partner/ Reseller/ DistributorFifteen-year partnership with a 30,000-person Mexican organization. Despite size differential, this relationship has proven exceptional due to product uniqueness and strong personal relationships. One of the company's most successful partnerships.
  • Ogna LaboratoricoreStrategic or Co-development PartnerItalian company specializing in dental products acquired by Primex. Nearly 90-year-old brand with exceptional market recognition in endodontics. Operates domestically in Italy while expanding internationally under its own brand. Products include local anesthetic portfolio (articaine, mepivicaine, lidocaine) and endodontic medical devices (CE marked).
  • Safetots.orgminorGTM or Marketing PartnerNon-profit initiative of leading paediatric anaesthesiologists that promotes safe conduct of anaesthesia in children. Supported by unrestricted educational grant from Primex Pharmaceuticals.
  • Troops SedationminorGTM or Marketing PartnerStandardized quality improvement tool from the International Committee for the Advancement of Procedural Sedation. Primex provides unrestricted educational grant support.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Primex Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Fresenius Kabi: Global leader in injectable anesthetics including a major propofol franchise. Direct competitor to Primex in propofol-based anesthesia and ICU sedation across hospital channels.
  • Hikma Pharmaceuticals: Specialty generic injectable manufacturer with hospital-channel focus in anesthesia and sedation. Highly comparable business model of branded generics distributed through hospital and institutional customers across multiple regions.
  • Aspen Pharmacare: Specialty pharma group that acquires and revitalizes branded generic portfolios globally, often in anesthesia and specialty hospital products. Closely mirrors Primex's acquire-revitalize-distribute playbook.

Emerging players

  • Sintetica: Swiss specialty injectable pharmaceutical company with focus on anesthesia, analgesia, and CNS products. Direct overlap in hospital-channel injectable anesthetics and similar mid-sized European specialty profile.
  • Paion AG: European specialty pharma developing and commercializing injectable anesthetic and sedation agents. Closely aligned with Primex's perioperative and procedural sedation therapeutic focus.
  • Ethypharm: French specialty pharma focused on branded generics and specialty hospital products with European and international reach. Comparable French-anchored specialty pharma profile and partner distribution approach.
  • Proveca: European specialty pharma dedicated to pediatric medicines. Directly comparable to Primex's pediatric sedation positioning and addresses similar unmet needs in pediatric formulations.

Broad incumbents

  • Norgine: European specialty pharma with portfolio of branded specialty products distributed through partners across multiple regions. Similar partner-led European commercial model and acquisition-driven growth.
  • Stada Arzneimittel: Large European generics and specialty pharma with broad hospital and consumer portfolio. Comparable in its mix of branded generics, specialty focus, and multi-country European presence.
  • Almirall: European specialty pharma focused on dermatology and specialty hospital products with partner-led international expansion. Similar mid-sized European specialty pharma profile with bolt-on acquisition strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Primex Pharmaceuticals social profiles

Digital presence

Primex Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

Primex Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Primex Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Primex Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Primex Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Primex Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Primex Pharmaceuticals

What does Primex Pharmaceuticals do?

Primex Pharmaceuticals is a commercial-stage specialty pharmaceutical company that develops, registers and distributes branded generic anesthetic and pediatric sedation products, primarily Recofol (propofol-based IV anesthetics) and OZALIN/OZASED (oral midazolam solution for pediatric procedural sedation), alongside the Ogna dental anesthetic and endodontic portfolio. The company outsources manufacturing and leverages a regional partner network (the "Primex Network") across 40+ countries to serve as local MAH, sales, marketing and distribution partners.

Is Primex Pharmaceuticals a public or private company?

Primex Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Primex Pharmaceuticals founded?

Primex Pharmaceuticals was founded in 2010. It employs 11 to 50 people.

Where is Primex Pharmaceuticals based?

Primex Pharmaceuticals is headquartered in Zug, Switzerland, in the Europe region.

How does Primex Pharmaceuticals make money?

Two revenue lines are on record. Product Sales are the primary driver. The others are licensing and Divestiture.

Who are Primex Pharmaceuticals's main competitors?

Direct peers on record are Fresenius Kabi, Hikma Pharmaceuticals and Aspen Pharmacare. Emerging players are Sintetica, Paion AG, Ethypharm and Proveca. Broad incumbents are Norgine, Stada Arzneimittel and Almirall.

Does Primex Pharmaceuticals have an API?

No public API is recorded for Primex Pharmaceuticals.

What industry is Primex Pharmaceuticals in?

Primex Pharmaceuticals's product category is Specialty Pharmaceuticals (Anesthesia and Pediatric Sedation). Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOZALIN® Continues to Receive Marketing Authorization Approvals Across EUPrimex Pharmaceuticals received marketing authorization for OZALIN (ADV6209) in Germany, Austria, Spain, Portugal, Ireland, Belgium, Greece, and Poland. The drug, an oral sedative for children, was previously approved in France, UK, Italy, Netherlands, Finland, Norway, and Denmark. The company cites a sales potential of over 100 million euros in Europe.news.cision.comPrimex Pharmaceuticals appoints Dan Spacie as Global Commercial HeadPrimex Pharmaceuticals appointed Dan Spacie as Global Commercial Head, joining from Syneos Health where he was President, Commercial, Europe. He will lead global commercialization, including the EU launch of OZALIN, and is based in Zug, Switzerland.PR NewswirePrimex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in FrancePrimex Pharmaceuticals and Nordic Group announced a strategic partnership to launch OZALIN®, an oral sedation solution for children older than 6 months, in France. The collaboration addresses a documented gap in approved pediatric anesthesia medications for premedication and procedural sedation, with OZALIN® already approved in several EU markets including France. Primex Pharmaceuticals aims to expand availability of OZALIN® across all EU member states.PR NewswirePrimex Pharmaceuticals Appoints Alan Knox as Group CEOPrimex Pharmaceuticals AG has appointed Alan Knox as Group CEO, succeeding Kari Sarvanto who stepped down. Knox brings over 30 years of pharmaceutical experience, including senior roles at AstraZeneca, Sandoz, and MSD. The company stated that operations remain on track to launch OZALIN® in the EU while continuing to grow its established Anaesthesia portfolio in existing and new markets.